Outcome of hepatitis C patients with and without hepatocellular carcinoma undergoing liver transplant
| Autor: | Bernhard Sauter, Swan N. Thung, Myron Schwartz, E Atillasoy, Albert D. Min, Romil Saxena, David C. Wolf, Henry C. Bodenheimer |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Liver Cirrhosis Male medicine.medical_specialty Carcinoma Hepatocellular Biological effect Gastroenterology Text mining Internal medicine medicine Humans Aged Hepatology business.industry Graft Survival Liver Neoplasms Hepatitis C Middle Aged medicine.disease digestive system diseases Liver Transplantation Surgery Survival Rate Transplantation Treatment Outcome surgical procedures operative Hepatocellular carcinoma Female Interferons Viral disease business Complication |
| Zdroj: | American Journal of Gastroenterology. 93:2148-2153 |
| ISSN: | 0002-9270 |
| Popis: | Hepatitis C virus (HCV) infection is associated with development of hepatocellular carcinoma (HCC). The aim of this study was to examine clinical characteristics and outcome of patients with HCV with or without HCC undergoing liver transplant.We reviewed the charts of all 55 patients transplanted between November 1990 and December 1996 for HCV cirrhosis with HCC and compared them with a control group of HCV patients without HCC. Patients with a history of alcohol abuse or HBsAg positivity were excluded. There were 37 men and 18 women, with a mean age of 57.6 yr (range, 19-70 yr) in the HCC group.There was no significant difference between the HCC and nonHCC groups regarding Child's class or United Network for Organ Sharing (UNOS) status at the time of transplant. Twenty-six (45%) patients were diagnosed or suspected of having HCC before transplant. Twenty-five patients (45.5%) had a single focus of HCC. Fourteen percent (seven of 50) of the patients with HCC had been treated with interferon, whereas 12% (six of 52) of patients in the nonHCC group had received interferon. Duration of interferon therapy ranged from 1 to 9 months. All interferon treatment occurred within 5 yr of transplant. A history of intravenous drug use or transfusion was identified in 37 (67%) of HCC patients. Thirty-two patients (58%) without HCC had a parenteral exposure. There was no significant difference in patient or graft survival rates between the patients with and without HCC.Approximately one-half of HCC was not detected before liver transplant. There was no significant difference in the mode of transmission, clinical status at the time of transplant, or outcome between the HCV patients with and without HCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|